References
1. Archie SR, Cucullo L. Harmful
Effects of Smoking Cannabis: A Cerebrovascular and Neurological
Perspective. Front Pharmacol.2019; 10: 1481-1481.
https://doi.org/10.3389/fphar.2019.01481
2. Borgan F, Beck K, Butler E,
McCutcheon R, Veronese M, Vernon A, et al. The effects of cannabinoid 1
receptor compounds on memory: a meta-analysis and systematic review
across species. Psychopharmacology. 2019; 236(11): 3257-3270.
https://doi.org/10.1007/s00213-019-05283-3
3. Kögel CC, López-Pelayo H,
Balcells-Olivero M, Colom J, Gual A. (2018). Psychoactive constituents
of cannabis and their clinical implications: a systematic review
Constituyentes psicoactivos del cannabis y sus implicaciones clínicas:
una revisión sistemática. Adicciones. 2018; 30(2): 140-152.
4.
4. Cohen K, Kapitány-Fövény M, Mama Y, Arieli M, Rosca P, Demetrovics Z,
et al. The effects of synthetic cannabinoids on executive function.
Psychopharmacology. 2017; 234(7): 1121-1134.
https://doi.org/10.1007/s00213-017-4546-4
5. NIDA. (2019). Marijuana as
Medicine. Retrieved 2020, May 29
https://www.drugabuse.gov/publications/drugfacts/marijuana-medicine
6. Ribeiro LI, Ind PW. Effect of
cannabis smoking on lung function and respiratory symptoms: a structured
literature review. NPJ Prim Care Respir Med. 2016; 26: 16071-16071.
https://doi.org/10.1038/npjpcrm.2016.71
7. Koren G, Cohen R. Medicinal Use of
Cannabis in Children and Pregnant Women. Rambam Maimonides Med J. 2020;
11(1). https://doi.org/10.5041/RMMJ.10382
8. Wang B, Kovalchuk A, Li D,
Ilnytskyy Y, Kovalchuk I, Kovalchuk O. (2020). In Search of Preventative
Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts
Modulate ACE2 Expression in COVID-19 Gateway Tissues. Preprints.
https://doi.org/10.20944/preprints202004.0315.v1
9. Hoffmann M, Kleine-Weber H,
Schroeder S, Krüger N, Herrler T, Erichsen S, et al. (2020). SARS-CoV-2
cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically
proven protease inhibitor. Cell.
https://doi.org/10.1016/j.cell.2020.02.052
10. Palmatier RW, Houston MB, Hulland
J. (2018). Review articles: Purpose, process, and structure. J Acad.
Mark Sci. https://doi.org/10.1007/s11747-017-0563-4
11. Williams K. (2014). The different
ways to smoke and consume cannabis Retrieved from
https://www.leafly.com/news/cannabis-101/the-complete-list-of-cannabis-delivery-methods
12. Baldwin J. (2020). Healthiest
Ways To Consume Weed: Better Than Smoking [Press release]. Retrieved
from https://www.weednews.co/healthiest-ways-to-consume-cannabis/
13. Romano L, Hazekamp A. An Overview
of Galenic Preparation Methods for Medicinal Cannabis. Curr Bioact
Compd. 2019; 15(2): 174-195.
https://doi.org/10.2174/1573407214666180612080412
14. NIDA. (2020, June 6). Marijuana
DrugFacts. https://www.drugabuse.gov/publications/drugfacts/marijuana
15. Franklin RM, Rosenthal E,
Franklin RM. (2019). Method for conducing concentrated cannabis oil to
be stable, emulsifiable and flavorless for use in hot beverages and
resulting powderized cannabis oil. Retrieved from
https://patents.google.com/patent/US9629886B2/en
16. Spindle TR, Cone EJ, Schlienz NJ,
Mitchell JM, Bigelow GE, Flegel R, et al. Urinary Excretion Profile of
11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH) Following Smoked and
Vaporized Cannabis Administration in Infrequent Cannabis Users. J Anal
Toxicoly. 2020; 44(1): 1-14. https://doi.org/10.1093/jat/bkz038
17. Bruni N, Della Pepa C,
Oliaro-Bosso S, Pessione E, Gastaldi D, Dosio F. Cannabinoid Delivery
Systems for Pain and Inflammation Treatment. Molecules. 2018; 23(10):
2478. https://doi.org/10.3390/molecules23102478
18. Holitzki H, Dowsett LE, Spackman
E, Noseworthy T, Clement F. Health effects of exposure to second-and
third-hand marijuana smoke: a systematic review. CMAJ open. 2017; 5(4):
E814. https://doi.org/10.9778/cmajo.20170112
19. International Agency for Research
on Cancer. (2019). IARC monographs on the identification of carcinogenic
hazards to humansList Classif. Agents Classif. by IARC Monogr (Vol. 1).
Lyon, France. Retrieved from
https://monographs.iarc.fr/agents-classified-by-the-iarc/.
20. Swenberg JA, Moeller BC, Lu K,
Rager JE, Fry RC, Starr TB. Formaldehyde carcinogenicity research: 30
years and counting for mode of action, epidemiology, and cancer risk
assessment. Toxicol Pathol. 2013; 41(2): 181-189.
https://doi.org/10.1177/0192623312466459
21. Abdel-Shafy HI, Mansour MS.
(2016). A review on polycyclic aromatic hydrocarbons: source,
environmental impact, effect on human health and remediation. EJP,
25(1): 107-123. https://doi.org/10.1016/j.ejpe.2015.03.011
22. Nakajima D, Yagishita M. (2018).
Carcinogenicity/MutagenicityPolycyclic Aromatic Hydrocarbons (pp.
235-244): https://doi.org/10.1007/978-981-10-6775-4_18
23. Dong H, Xian Y, Li H, Bai W, Zeng
X. Potential carcinogenic heterocyclic aromatic amines (HAAs) in
foodstuffs: Formation, extraction, analytical methods, and mitigation
strategies. Comprehensive Compr Rev Food Sci. 2020; 19(2): 365-404.
https://doi.org/10.1111/1541-4337.12527
24. Tan SLW, Chadha S, Liu Y,
Gabasova E, Perera D, Ahmed K, et al. (2017). A class of environmental
and endogenous toxins induces BRCA2 haploinsufficiency and genome
instability. Cell, 169(6): 1105-1118. e15.
https://doi.org/10.1016/j.cell.2017.05.010
25. NCBI. Isobutylene. Retrieved June
19, 2020, from PubChem Database
https://pubchem.ncbi.nlm.nih.gov/compound/Isobutylene
26. Coddington H. (2017). Dabbing, Terpenes, and the Possibility of
Carcinogens.
https://gopurepressure.com/blogs/rosin-education/dabbing-terpenes-and-the-possibility-of-carcinogens
27. World Health Organization.
(2018). Delta-9-tetrahydrocannabinol WHO Expert Committee on Drug
Dependence Critical Review. Retrieved from
https://www.who.int/medicines/access/controlled-substances/THCv1.pdf?ua=1
28. Russo C, Ferk F, Mišík M, Ropek
N, Nersesyan A, Mejri D, et al. Low doses of widely consumed
cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and
chromosomal aberrations in human-derived cells. Arch Toxicol. 2019;
93(1): 179-188. https://doi.org/10.1007/s00204-018-2322-9
29. Graves BM, Johnson TJ, Nishida
RT, Dias RP, Savareear B, Harynuk JJ, et al. Comprehensive
characterization of mainstream marijuana and tobacco smoke. Sci Rep
2020; 10(1): 1-12.
https://doi.org/10.1038/s41598-020-63120-6
30. Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D.
Association Between Marijuana Use and Risk of Cancer: A Systematic
Review and Meta-analysis. JAMA network open. 2019; 2(11):
e1916318-e1916318.
https://doi.org/10.1001/jamanetworkopen.2019.16318
31. Callaghan RC, Allebeck P, Akre O,
McGlynn KA, Sidorchuk A. Cannabis use and incidence of testicular
cancer: a 42-year follow-up of Swedish men between 1970 and 2011. Cancer
Epidemiol Biomarkers Prev. 2017; 26(11): 1644-1652.
https://doi.org/10.1158/1055-9965
32. Radhakrishnan R, Wilkinson ST,
D’Souza DC. (2014). Gone to Pot - A Review of the Association between
Cannabis and Psychosis. Front Psychiatry. 2014; 5: 54-54.
https://doi.org/10.3389/fpsyt.2014.00054
33. National Academies of Sciences Engineering and Medicine. (2017). The
health effects of cannabis and cannabinoids: The current state of
evidence and recommendations for research: National Academies Press.
Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK425753/.
34. Cohen K, Weizman A, Weinstein A.
Positive and negative effects of cannabis and cannabinoids on health.
ASCPT. 2019; 105(5): 1139-1147. https://doi.org/10.1002/cpt.1381
35. Byers C. (2017). Marijuana
Smoking and the Risk of Developing COPD, Lung Cancer, And/or Chronic
Respiratory Symptoms: A Systematic Review. The University of Arizona.
Retrieved from
https://repository.arizona.edu/bitstream/handle/10150/623758/ByersC%20Poster.pdf?sequence=1&isAllowed=y
36. Wang X, Derakhshandeh R, Liu J,
Narayan S, Nabavizadeh P, Le S, et al. One minute of marijuana
secondhand smoke exposure substantially impairs vascular endothelial
function. JAHA. 2016; 5(8): e003858.
https://doi.org/10.1161/JAHA.116.003858
37. Hartman RL, Huestis MA. (2013).
Cannabis effects on driving skills. Clin Chem, 59(3): 478-492.
38. NIDA. (2020, April 6). Marijuana.
Retrieved 2020, June 10
https://www.drugabuse.gov/publications/research-reports/marijuana/there-link-between-marijuana-use-psychiatric-disorders
39. Bloomfield MAP, Ashok AH, Volkow
ND, Howes OD. The effects of Δ(9)-tetrahydrocannabinol on the dopamine
system. Nature. 2016; 539(7629): 369-377.
https://doi.org/10.1038/nature20153
40. Beale C, Broyd SJ, Chye Y, Suo C,
Schira M, Galettis P, et al. Prolonged Cannabidiol Treatment Effects on
Hippocampal Subfield Volumes in Current Cannabis Users. Cannabis
Cannabinoid Res. 2018; 3(1): 94-107.
https://doi.org/10.1089/can.2017.0047
41. Wolff V, Jouanjus E. Strokes are possible complications of
cannabinoids use. Epilepsy & Behavior. 2017; 70: 355-363.
https://doi.org/10.1016/j.yebeh.2017.01.031
42. Wolff V, Lauer V, Rouyer O,
Sellal F, Meyer N, Raul JS, et al. Cannabis use, ischemic stroke, and
multifocal intracranial vasoconstriction: a prospective study in 48
consecutive young patients. Stroke. 2011; 42(6): 1778-1780.
https://doi.org/10.1161/STROKEAHA.110.610915
43. Sharma P, Murthy P, Bharath MMS.
Chemistry, metabolism, and toxicology of cannabis: clinical
implications. Iran J Psychiatry. 2012; 7(4): 149-156.
44. Lee A, Ahmed C, Campbell A, Garber M, Palmisiano M, Neil D, et al.
(2020). The Financial and Psychosocial Impact of Medicinal Cannabis.
45. de Carvalho Reis R, Almeida KJ,
da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Efficacy and
adverse event profile of cannabidiol and medicinal cannabis for
treatment-resistant epilepsy: Systematic review and meta-analysis.
Epilepsy Behav. 2020; 102: 106635.
https://doi.org/10.1016/j.yebeh.2019.106635
46. Perisetti A, Rimu AH, Khan SA,
Bansal P, Goyal H. (2020). Role of cannabis in inflammatory bowel
diseases. Ann Gastroenterol. 2020; 33(2): 134.
https://doi.org/10.20524/aog.2020.0452
47. Kramer JL (2015) Medical
marijuana for cancer. Ca-Cancer J Clin, 65(2), 109-122.
48. Desai AN, Patel P. Stopping the
Spread of COVID-19. JAMA. 2020; 323(15): 1516-1516.
https://doi.org/10.1001/jama.2020.4269
49. Abany Z. Coronavirus: The tide is
coming for medicinal cannabis. 2020; Available from:
https://www.dw.com/en/coronavirus-the-tide-is-coming-for-medicinal-cannabis/a-53371342.
50. Hill KP. Cannabinoids and the
Coronavirus. Cannabis Cannabinoid Res. 2020; 5(2).
https://doi.org/10.1089/can.2020.0035
51. Le J. (2019). Overview of
Pharmacokinetics Retrieved from
https://www.msdmanuals.com/professional/clinical-pharmacology/pharmacokinetics/overview-of-pharmacokinetics
52. Millar SA, Stone NL, Yates AS,
O’Sullivan SE. A systematic review on the pharmacokinetics of
cannabidiol in humans. Front Pharmacol. 2018; 9: 1365.
https://doi.org/10.3389/fphar.2018.01365
53. Klumpers LE, Thacker DL. A brief
background on cannabis: From plant to medical indications. J AOAC Int.
2019; 102(2): 412-420. https://doi.org/10.5740/jaoacint.18-0208
54. Lucas CJ, Galettis P, Schneider
J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J
Clin Pharmacol. 2018; 84(11): 2477-2482.
https://doi.org/10.1111/bcp.13710
55. Grotenhermen F. Clinical
Pharmacokinetics of Cannabinoids. J Cannabis Ther. 2003; 3(1): 3-51.
https://doi.org/10.1300/J175v03n01_02
56. Kis B, Ifrim FC, Buda V, Avram S,
Pavel IZ, Antal D, et al. Cannabidiol—From plant to human body: A
promising bioactive molecule with multi-target effects in cancer. Int J
Mol Sci. 2019; 20(23): 5905. https://doi.org/10.3390/ijms20235905
57. Lucas CJ, Galettis P, Song S,
Solowij N, Reuter SE, Schneider J, et al. Cannabinoid disposition after
human intraperitoneal use: an insight into intraperitoneal
pharmacokinetic properties in metastatic cancer. Clin Ther. 2018; 40(9):
1442-1447. https://doi.org/10.1016/j.clinthera.2017.12.008
58. Heuberger JA, Guan Z, Oyetayo O
O, Klumpers L, Morrison PD, Beumer TL, et al. Population pharmacokinetic
model of THC integrates oral, intravenous, and pulmonary dosing and
characterizes short-and long-term pharmacokinetics. Clin Pharmacokinet.
2015; 54(2): 209-219. https://doi.org/10.1016/j.vascn.2017.02.003